---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-100245"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-09-15T23:59:59+00:00"
generated_at: "2026-06-23T09:17:25.148701+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low

## Summary
- Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.
- ELX-02 was well tolerated; no treatment-related serious adverse events reported.
- Evidence of activity seen in patients with higher baseline sweat chloride (p=0.00013 at Day 35).
- Steady-state lung drug levels averaged 2 µM, only 20% of lowest preclinical active concentration.
- Company plans to start proof-of-concept trial for ELX-02 in Alport syndrome later in 2022.

## SEC filing metadata
- accession: 0001104659-22-100245
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/0001104659-22-100245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922100245/tm2225930d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-100245
- JSON: https://secwatch.observer/filing/0001104659-22-100245.json
- Plain text: https://secwatch.observer/filing/0001104659-22-100245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.